

NITROGEN BRIDGEHEAD COMPOUNDS PART 59<sup>1</sup>. NUCLEOPHILIC SUBSTITUTION  
REACTIONS OF 9-BROMO-6,7,8,9-TETRAHYDRO-4H-PYRIDO[1,2-a]PYRIMIDIN-4-ONES

István Bitter

Department of Organic Chemical Technology, Technical University  
H-1111 Budapest, Hungary

Gábor Tóth

NMR Laboratory of the Institute of General and Analytical Chemistry  
Technical University, H-1111 Budapest, Hungary



István Hermecz and Zoltán Mészáros

CHINOIN Pharmaceutical and Chemical Works, P.O.Box 110, H-1325,  
Budapest, Hungary

Abstract - Halogen replacement of 9-bromo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-ones with C-, N-, O-, and S-nucleophiles can be readily accomplished.

During the course of our investigations concerning the isomerism and tautomerism of biologically active tetrahydropyrido[1,2-a]pyrimidin-4-ones we have prepared a great number of derivatives containing different groups in the position 9. These compounds could be prepared by electrophilic substitution reaction with aldehydes<sup>2</sup>, halogen<sup>3a,b</sup>, diazonium salts<sup>3c,4</sup>, isocyanates<sup>5</sup>, iminium chlorides<sup>6</sup> and nitrous acid<sup>7</sup> on the activated piperidine ring<sup>8</sup> and recently by nucleophilic substitution of the 9-bromine atom<sup>3c,4b,7,9</sup>. Since the halogen atom proved to be most reactive owing to the activating effect of the neighbouring pyrimidone ring, compound 1 readily reacted with simple nucleophiles to give compounds (2-5) (40-60%), as shown in Scheme 1.


Bromine replacements were carried out in DMF (10 mmol of compound 1 + 15 mmol of NaX, t = 25°C, 1-6 h)<sup>10</sup>. Strong S-nucleophiles of carbamate and urea type, however, smoothly reacted with compounds 1 a,b,c even in acetone at room temperature resulting in the formation of dithiocarbamates (6,7) and isothiuronium salts (8-10) respectively<sup>11</sup> (Scheme 1).



<u>8a</u>	$R^3, R^4 = H$	<u>6a, c</u>	$R^1 + R^2 = (CH_2CH_2)_2O$
<u>9a, c</u>	$R^3 = H, R^4 = -CH_2CH_2-$	<u>7a, b, c</u>	$R^1 + R^2 = (CH_2)_4$
<u>10a, b, c</u>	$R^3, R^4 = Me$		

Scheme 1.

Earlier we have described<sup>6</sup> that 6-methyltetrahydropyrido[1,2-a]pyrimidin-4-ones substituted in the position 9 may exist in cis and trans isomer (A,C) and tautomer (B) forms (Scheme 2).



Scheme 2.

Enamine form (B) can be distinguished in  $^1\text{H}$  NMR by the lack of H-9 signal, NH signal above 10 ppm (chelation), and doublet signal of H-2 (not always) while in  $^{13}\text{C}$  NMR, by the  $\text{sp}^2$  character of C-9. Imine forms (A,C) can be differentiated on the bases of the coupling constants between H-9<sub>eq</sub> or H-9<sub>ax</sub> and H-8 protons and the  $\text{\gamma-gauche}$  interaction of R substituent and C-7 atom in  $^{13}\text{C}$  NMR. In case of  $\text{R}^1=\text{CONR}_2$  and COOR we succeeded in identifying every species by NMR spectral analysis<sup>8a</sup>. Now having prepared new derivatives with different characteristic groups in the position 9 we wanted to gain more data about the imine-enamine tautomerism. According to  $^1\text{H}$  NMR investigations the ratios of A-B-C forms are summarized in the table.

Isomer ratio and characteristic NMR data of compounds 1-7 and 10.

Comp.	B	A(trans)	C(cis)
	Enamine		Imine
<u>1a</u> <sup>x</sup>	-	(82%), Me 1.28d	(18%), Me 1.42d
<u>2a</u> <sup>+</sup>	-	(93%), H <sub>eq</sub> -9 5.66t	(7%), Me 1.38d
<u>3a</u> <sup>+</sup>	-	-	(100%), H <sub>ax</sub> -9 3.80
<u>4a</u> <sup>x</sup>	(90%) Me 1.16d, NH 11,11	(A+B:10%), Me 1.21d	
<u>5a</u> <sup>x</sup>	(100%) Me 1.26d, NH 13.69s	-	-
<u>5b</u> <sup>x</sup>	(100%) Me 1.12d, NH 13.74s	-	-
<u>5c</u> <sup>x</sup>	(100%) Me 1.12d, NH 13.29	-	-
<u>6a</u> <sup>+</sup>	-	A(50%), C(50%), Me 1.45d, 1.46d, H-2 8.88s	
<u>7a</u> <sup>+</sup>	-	A(50%), C(50%), Me 1.47d, 1.48d, H-2 8.89s	
<u>10a</u> <sup>+</sup>	(20%) Me 1.17d, H-2 8.20s	(A+C:80%), Me 1.41d(50%), 1.43d(30%), H-2 8.74s(80%)	
<u>10b</u> <sup>+</sup>	(50%) Me 1.13d, H-2 8.16s	(A+B:50%) H-2 8.54s (50%)	
<u>10c</u> <sup>x</sup>	(38%) Me 1.12d, H-2 7.97s	(A+C:62%), Me 1.32d(25%), 1.33d(37%), H-2 8.65s(25%)	8.68s(37%)

Solvent:  $^x\text{DMSO-d}_6$ ,  $^+_{\text{CDCl}}_3$

The data of the table indicate that the A $\rightleftharpoons$ B $\rightleftharpoons$ C equilibria is remarkably affected by strongly electron withdrawing groups (NO<sub>2</sub>, CN:predominant enamine structure) and strongly electron releasing groups (OAc,SCSNR<sup>1</sup>R<sup>2</sup>, I : exclusive imine form with different cis/trans ratio). Compounds 10, however, are characteristic examples of the simultaneous existence of the cis and trans isomers and the enamine tautomer as well.

#### REFERENCES AND NOTES

1. Part 58. I.Bitter, G.Tóth, B.Pete, I.Hermecz, K.Simon, and Z.Mészáros, Heterocycles, 1986, 24, 69.
- 2a. I.Hermecz, Z.Mészáros, L.Vasvári-Debreczy, Á.Horváth, S.Virág, and J.Sipos Arzneim.Forsch., 1979, 29, 1833.
- 2b. M.Balogh, I.Hermecz, and Z.Mészáros, Synthesis, 1984, 582.
- 3a. Z.Mészáros, J.Knoll, P.Szentmiklósí, Á.Dávid, G.Horváth, and I.Hermecz, Arzneim.Forsch., 1972, 22, 815.
- 3b. I.Hermecz, T.Breining, Z.Mészáros, G.Tóth, and I.Bitter, Heterocycles, 1980, 14, 1953.
- 3c. G.Tóth, Á.Szöllősy, A.Almásy, B.Podányi, I.Hermecz, T.Breining, and Z.Mészáros, Org. Magn.Reson., 1983, 21, 687.
- 4a. I.Hermecz, T.Breining, Z.Mészáros, Á.Horváth, L.Vasvári-Debreczy, F.Dessy, C. De Vos, and L.Rodriguez, J.Med.Chem., 1982, 25, 1140.
- 4b. I.Hermecz, T.Breining, Z.Mészáros, J.Kokosi, L.Mészáros, F.Dessy, and C. De Vos, J.Med. Chem., 1983, 26, 1126.
5. I.Bitter, I.Hermecz, G.Tóth, P.Dvortsák, Z.Bende, and Z.Mészáros, Tetrahedron Lett., 1979, 5039.
- 6a. I.Hermecz, I.Bitter, Á.Horváth, G.Tóth, and Z.Mészáros, Tetrahedron Lett., 1979, 2557.
- 6b. G.Tóth, C.De la Cruz, I.Bitter, I.Hermecz, B.Pete, and Z.Mészáros, Org.Magn.Reson., 1982, 20, 229.
- 6c. Á.Horváth, I.Hermecz, L.Vasvári-Debreczy, K.Simon, M.Pongor-Csákvári, Z.Mészáros, and G.Tóth, J.Chem.Soc.Perkin Trans I, 1983, 369.
7. I.Hermecz, T.Breining, L.Vasvári-Debreczy, Á.Horváth, Z.Mészáros, I.Bitter, C. De Vos, and L.Rodriquez, J.Med.Chem., 1983, 26, 1494.

- 8a. G.Tóth, Á.Szöllősy, B.Podányi, I.Hermecz, Á.Horváth, Z.Mészáros, and I.Bitter, J.Chem.Soc.Perkin Trans II, 1983, 165.
- b. G.Tóth, Á.Szöllősy, B.Podányi, I.Hermecz, Á.Horváth, Z.Mészáros, and I.Bitter, ibid., 1983, 1409.
9. I.Hermecz, P.R.Surján, T.Breining, K.Simon, G.Horváth, Z.Mészáros, M.Kajtár, and G.Tóth, J.Chem.Soc.Perkin Trans II, 1983, 1413.
10. 1a,b,c, were prepared by the bromination of the corresponding 3-substituted 4-oxo-6-methyl-6,7,8,9-tetrahydro[1,2-a]pyrimidine with equimolar Br<sub>2</sub> in AcOH+NaOAc at 25-30°C<sup>2,3b</sup>. Trans: cis ratio=4:1 2a mp: 220°C, Y: 52 %, 3a mp 152-154°C, Y: 56 %, 4a mp 250°C, Y: 46 %, 5 mp 240-242°C Y: 61 % 5b mp 216-218°C, Y: 40 %, 5c mp 228°C, Y: 62 %.
11. 6a mp 198-200°C, Y: 75 %, 6c mp 158-160°C, Y: 70 %, 7a mp 220°C, Y: 69 % 7b mp 158-160°C, Y: 49 %, 7c mp 156°C, Y: 66 %, 8a mp 182-183°C, Y: 85 %, 9a mp 204-206°C, Y: 75 %, 9c mp 160-164°C, Y: 81 %, 10a mp 151-153°C, Y: 75 %, 10b mp 150-151°C, Y: 61 % 10c mp 156-157°C, Y: 80 %.

Received, 17th November, 1986